Genmab — Juni 2019
-
Then as it relates to DR5/5 HexaBody and the CD3xCD20 DuoBody programs, we're doing dose escalation for both and it's going well, I can tell you for both programs. And when we think about potentially partnering either one of these programs, I think there's a good chance that we need a partner because the market could potentially be huge for a program like the DR5/DR5 HexaBody program.
-
It's a well-validated target preclinically, and we have seen some very encouraging signs of early activity already with only a handful of patients already reflected up at the Capital Markets Day last September. So we would definitely expect that we need a partner for that program to maximize the potential of that program if we see good signs of clinical efficacy with our HexaBody product.
-
And the same holds actually for the CD3xCD20 bispecific program. There's considerable excitement now in the hematology field because of the Regeneron and Roche programs. Yesterday, the Regeneron program created some lesser excitement because of some fatalities apparently in one of their trials. But we have a very different molecule, which preclinically seems to be at least 100-fold more potent than the Regeneron CD3xCD20 and 2 to fourfold more potent preclinically than the best Roche program. So
-
We expect data for the CD3xCD20 before or at the ASH meeting this year. So I think it's heating up quite well, Sachin. And I think we could potentially see partnerships for both of these programs to maximize the potential for the CD3xCD20, the very competitive hematological area. Now a little bit behind Roche and Regeneron but with a very differentiated molecule. This is given subcutaneously and preclinically. It's very, very much more potent than these other programs, and we use a different way
-
@Plimsoller ? i don't know? you have holiday on monday... (again...)
-
@E L Yes Sir
-
You are right that the stock exchange is closed tomorrow - most people are however working.
-
Me too. I only have half a day off
-
Celgene viser kliniske data for arvtager til super-blockbuster mod knoglemarvskræft
Amerikanske Celgene har fremlagt positive kliniske data for et nyt immunmodulerende middel til behandling af knoglemarvskræft, som ser ud til at kunne hjælpe patienter, når behandling med Genmabs Darzalex eller selskabets egen storsællert Revlimid fejler.
(medwatch.dk)
-
@Sukkeralf are they talking about Iberdomide there?
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind